LIVIVO - Search results -

Search results

Result 1 - 10 of total 10

Search options

Article ; Online: The presence of busulfan metabolites and pharmacometabolomics in plasma drawn immediately before allograft infusion in hematopoietic cell transplant recipients.

McCune, Jeannine S / Navarro, Sandi L / Risler, Linda J / Phillips, Brian R / Ren, Suping / Schoch, H Gary / Baker, K Scott

Clinical and translational science

2023 Volume 16, Issue 12, Page(s) 2577–2590

Abstract: Busulfan is hepatically metabolized through glutathione (GSH) conjugation; in vitro, this process depletes hepatocyte GSH stores and generates the cytotoxic metabolite γ-glutamyldehydroalanylglycine, which is too unstable to be quantitated in vivo. We ... ...

Abstract	Busulfan is hepatically metabolized through glutathione (GSH) conjugation; in vitro, this process depletes hepatocyte GSH stores and generates the cytotoxic metabolite γ-glutamyldehydroalanylglycine, which is too unstable to be quantitated in vivo. We sought to evaluate if pre-graft (i.e., immediately before allograft infusion) concentrations of busulfan metabolites' and of endogenous metabolomic compounds (EMCs) representing the glutathione pathway were associated with clinical outcomes in hematopoietic cell transplant (HCT) recipients receiving busulfan. The clinical outcomes evaluated were relapse, acute graft versus host disease (GVHD), chronic GVHD, non-relapse mortality, and neutrophil nadir. In pre-graft samples obtained from patients immediately before allograft infusion, our objectives were to evaluate for: (1) the presence of busulfan and its metabolites tetrahydrothiophenium ion (THT+), tetrahydrothiophene 1-oxide, sulfolane, and 3-hydroxysulfolane (N = 124); (2) EMCs using a global metabolomics assay (N = 77); and (3) the association of the busulfan metabolites and the EMCs with clinical outcomes. In the pre-graft samples, busulfan and THT+ could not be detected. THT 1-oxide, sulfolane, and 3-hydroxysulfolane were quantitated in 9.6%, 26%, and 58% of pre-graft samples; their concentrations were not associated with clinical outcomes. Four pre-graft EMCs were statistically significantly associated with the neutrophil nadir. The pre-graft EMCs were not associated with the other clinical outcomes. In conclusion, busulfan's metabolites are present in patients' plasma immediately before allograft infusion; the neutrophil nadir is associated with pre-graft EMCs. Future research should investigate the association of clinical outcomes with the concentrations of busulfan's metabolites and EMCs in the pre-graft plasma from allogeneic HCT recipients.
MeSH term(s)	Humans ; Busulfan ; Transplant Recipients ; Hematopoietic Stem Cell Transplantation ; Graft vs Host Disease/etiology ; Glutathione/metabolism ; Allografts
Chemical Substances	Busulfan (G1LN9045DK) ; sulfolane (Y5L06AH4G5) ; Glutathione (GAN16C9B8O)
Language	English
Publishing date	2023-10-10
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural
ZDB-ID	2433157-0
ISSN	1752-8062 ; 1752-8054
ISSN (online)	1752-8062
ISSN	1752-8054
DOI	10.1111/cts.13651
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Prediction of Busulfan Clearance by Predose Plasma Metabolomic Profiling.

McCune, Jeannine S / Navarro, Sandi L / Baker, K Scott / Risler, Linda J / Phillips, Brian R / Randolph, Timothy W / Shireman, Laura / Schoch, H Gary / Deeg, H Joachim / Zhang, Yuzheng / Men, Alex / Maton, Loes / Huitema, Alwin D R

Clinical pharmacology and therapeutics

2022 Volume 113, Issue 2, Page(s) 370–379

Abstract: Intravenous busulfan doses are often personalized to a target plasma exposure (targeted busulfan) using an individual's busulfan clearance (BuCL). We evaluated whether BuCL could be predicted by a predose plasma panel of 841 endogenous metabolomic ... ...

Abstract	Intravenous busulfan doses are often personalized to a target plasma exposure (targeted busulfan) using an individual's busulfan clearance (BuCL). We evaluated whether BuCL could be predicted by a predose plasma panel of 841 endogenous metabolomic compounds (EMCs). In this prospective cohort of 132 hematopoietic cell transplantation (HCT) patients, all had samples collected immediately before busulfan administration (preBU) and 96 had samples collected 2 weeks before busulfan (2-week-preBU). BuCL was significantly associated with 37 EMCs after univariate linear regression analysis and controlling for false discovery (< 0.05) in the 132 preBU samples. In parallel, with preBU samples, we included all 841 EMCs in a least absolute shrinkage and selection operator-penalized regression which selected 13 EMCs as predominantly associated with BuCL. Then, we constructed a prediction model by estimating coefficients for these 13 EMCs, along with sex, using ordinary least-squares. When the resulting linear prediction model was applied to the 2-week-preBU samples, it explained 40% of the variation in BuCL (adjusted R
MeSH term(s)	Humans ; Busulfan ; Prospective Studies ; Precision Medicine ; Pharmacogenetics ; Metabolomics ; Hematopoietic Stem Cell Transplantation/methods ; Transplantation Conditioning/methods
Chemical Substances	Busulfan (G1LN9045DK)
Language	English
Publishing date	2022-12-26
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural
ZDB-ID	123793-7
ISSN	1532-6535 ; 0009-9236
ISSN (online)	1532-6535
ISSN	0009-9236
DOI	10.1002/cpt.2794
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 20: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Alveolar levels of immuno-inflammatory mediators in diffuse alveolar hemorrhage after allogeneic transplant.

Vande Vusse, Lisa K / Wurfel, Mark M / Madtes, David M / Schoch, H Gary / Harju-Baker, Susanna / Hill, Joshua A / Jerome, Keith R / Boeckh, Michael / Watkins, Timothy R

Bone marrow transplantation

2018 Volume 53, Issue 9, Page(s) 1206–1209

MeSH term(s)	Adult ; Female ; Hematopoietic Stem Cell Transplantation/adverse effects ; Hemorrhage/etiology ; Hemorrhage/immunology ; Humans ; Inflammation Mediators/analysis ; Male ; Middle Aged ; Pneumonia/etiology ; Pulmonary Alveoli/chemistry ; Pulmonary Alveoli/pathology ; Transplantation, Homologous/adverse effects
Chemical Substances	Inflammation Mediators
Keywords	covid19
Language	English
Publishing date	2018-04-18
Publishing country	England
Document type	Letter ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	632854-4
ISSN	1476-5365 ; 0268-3369 ; 0951-3078
ISSN (online)	1476-5365
ISSN	0268-3369 ; 0951-3078
DOI	10.1038/s41409-018-0168-7
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2168: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Impact of donor age on outcome after allogeneic hematopoietic cell transplantation.

Rezvani, Andrew R / Storer, Barry E / Guthrie, Katherine A / Schoch, H Gary / Maloney, David G / Sandmaier, Brenda M / Storb, Rainer

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

2014 Volume 21, Issue 1, Page(s) 105–112

Abstract: As older patients are eligible for allogeneic hematopoietic cell transplantation (HCT), older siblings are increasingly proposed as donors. We studied the impact of donor age on the tempo of hematopoietic engraftment and donor chimerism, acute and ... ...

Abstract	As older patients are eligible for allogeneic hematopoietic cell transplantation (HCT), older siblings are increasingly proposed as donors. We studied the impact of donor age on the tempo of hematopoietic engraftment and donor chimerism, acute and chronic graft-versus-host disease (GVHD), and nonrelapse mortality (NRM) among 1174 consecutive patients undergoing myeloablative and 367 patients undergoing nonmyeloablative HCT from HLA-matched related or unrelated donors with granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell allografts. Sustained engraftment rates were 97% and 98% in patients undergoing myeloablative and nonmyeloablative conditioning, respectively, for grafts from donors < 60 years old (younger; n = 1416) and 98% and 100%, respectively, for those from donors ≥ 60 years old (older; n = 125). No significant differences were seen in the tempo of neutrophil and platelet recoveries and donor chimerism except for an average 1.3-day delay in neutrophil recovery among myeloablative patients with older donors (P = .04). CD34(+) cell dose had an independent effect on the tempo of engraftment. Aged stem cells did not convey an increased risk of donor-derived clonal disorders after HCT. Myeloablative and nonmyeloablative recipients with older sibling donors had significantly less grade II to IV acute GVHD than recipients with grafts from younger unrelated donors. Rates of grade III and IV acute GVHD, chronic GVHD, and NRM for recipients with older donors were not significantly different from recipients with younger donors. In conclusion, grafts from donors ≥ 60 years old do not adversely affect outcomes of allogeneic HCT compared with grafts from younger donors.
MeSH term(s)	Acute Disease ; Aged ; Antineoplastic Agents/therapeutic use ; Chronic Disease ; Female ; Graft Survival ; Graft vs Host Disease/immunology ; Graft vs Host Disease/mortality ; Graft vs Host Disease/pathology ; Hematologic Neoplasms/immunology ; Hematologic Neoplasms/mortality ; Hematologic Neoplasms/pathology ; Hematologic Neoplasms/therapy ; Hematopoietic Stem Cell Transplantation ; Humans ; Male ; Middle Aged ; Severity of Illness Index ; Siblings ; Survival Analysis ; Tissue Donors ; Transplantation Chimera ; Transplantation Conditioning/methods ; Transplantation, Homologous ; Treatment Outcome ; Whole-Body Irradiation
Chemical Substances	Antineoplastic Agents
Language	English
Publishing date	2014-09-30
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	1474865-4
ISSN	1523-6536 ; 1083-8791
ISSN (online)	1523-6536
ISSN	1083-8791
DOI	10.1016/j.bbmt.2014.09.021
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5082: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 462: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Predictive Value of Clinical Findings and Plasma Biomarkers after Fourteen Days of Prednisone Treatment for Acute Graft-versus-host Disease.

McDonald, George B / Tabellini, Laura / Storer, Barry E / Martin, Paul J / Lawler, Richard L / Rosinski, Steven L / Schoch, H Gary / Hansen, John A

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

2017 Volume 23, Issue 8, Page(s) 1257–1263

Abstract: We examined the hypothesis that plasma biomarkers and concomitant clinical findings after initial glucocorticoid therapy can accurately predict failure of graft-versus-host-disease (GVHD) treatment and mortality. We analyzed plasma samples and clinical ... ...

Abstract	We examined the hypothesis that plasma biomarkers and concomitant clinical findings after initial glucocorticoid therapy can accurately predict failure of graft-versus-host-disease (GVHD) treatment and mortality. We analyzed plasma samples and clinical data in 165 patients after 14 days of glucocorticoid therapy and used logistic regression and areas under receiver-operating characteristic curves (AUC) to evaluate associations with treatment failure and nonrelapse mortality (NRM). Initial treatment of GVHD was unsuccessful in 49 patients (30%). For predicting GVHD treatment failure, the best clinical combination (total serum bilirubin and skin GVHD stage: AUC, .70) was competitive with the best biomarker combination (T cell immunoglobulin and mucin domain 3 [TIM3] and [interleukin 1 receptor family encoded by the IL1RL1 gene, ST2]: AUC, .73). The combination of clinical features and biomarker results offered only a slight improvement (AUC, .75). For predicting NRM at 1 year, the best clinical predictor (total serum bilirubin: AUC, .81) was competitive with the best biomarker combination (TIM3 and soluble tumor necrosis factor receptor-1 [sTNFR1]: AUC, .85). The combination offered no improvement (AUC, .85). Infection was the proximate cause of death in virtually all patients. We conclude that after 14 days of glucocorticoid therapy, clinical findings (serum bilirubin, skin GVHD) and plasma biomarkers (TIM3, ST2, sTNFR1) can predict failure of GVHD treatment and NRM. These biomarkers reflect counter-regulatory mechanisms and provide insight into the pathophysiology of GVHD reactions after glucocorticoid treatment. The best predictive models, however, exhibit inadequate positive predictive values for identifying high-risk GVHD cohorts for investigational trials, as only a minority of patients with high-risk GVHD would be identified and most patients would be falsely predicted to have adverse outcomes.
MeSH term(s)	Acute Disease ; Adolescent ; Adult ; Aged ; Aged, 80 and over ; Bilirubin/blood ; Biomarkers/blood ; Child ; Female ; Graft vs Host Disease/blood ; Graft vs Host Disease/drug therapy ; Graft vs Host Disease/mortality ; Hepatitis A Virus Cellular Receptor 2/blood ; Humans ; Interleukin-1 Receptor-Like 1 Protein/blood ; Male ; Middle Aged ; Predictive Value of Tests ; Prednisolone/administration & dosage ; Receptors, Tumor Necrosis Factor, Type I/blood ; Time Factors
Chemical Substances	Biomarkers ; HAVCR2 protein, human ; Hepatitis A Virus Cellular Receptor 2 ; IL1RL1 protein, human ; Interleukin-1 Receptor-Like 1 Protein ; Receptors, Tumor Necrosis Factor, Type I ; Prednisolone (9PHQ9Y1OLM) ; Bilirubin (RFM9X3LJ49)
Language	English
Publishing date	2017-08
Publishing country	United States
Document type	Journal Article
ZDB-ID	1474865-4
ISSN	1523-6536 ; 1083-8791
ISSN (online)	1523-6536
ISSN	1083-8791
DOI	10.1016/j.bbmt.2017.04.029
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5082: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 462: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Serum bilirubin levels and mortality after myeloablative allogeneic hematopoietic cell transplantation.

Gooley, Ted A / Rajvanshi, Pankaj / Schoch, H Gary / McDonald, George B

Hepatology (Baltimore, Md.)

2005 Volume 41, Issue 2, Page(s) 345–352

Abstract: Many patients who undergo hematopoietic cell transplantation experience liver injury. We examined the association of serum bilirubin levels with nonrelapse mortality by day +200, testing the hypothesis that the duration of jaundice up to a given point in ...

Abstract	Many patients who undergo hematopoietic cell transplantation experience liver injury. We examined the association of serum bilirubin levels with nonrelapse mortality by day +200, testing the hypothesis that the duration of jaundice up to a given point in time provides more prognostic information than either the maximum bilirubin value or the value at that point in time. We studied 1,419 consecutive patients transplanted from allogeneic donors. Total serum bilirubin values up to day +100, death, or relapse were retrieved-along with nonrelapse mortality by day +200 as an outcome measure--using Cox regression models with each bilirubin measure modeled as a time-dependent covariate. The bilirubin value at a particular point in time provided the best fit to the model for mortality. With bilirubin at a point in time modeled as an 8th-degree polynomial, an increase in bilirubin from 1 to 3 mg/dL is associated with a mortality hazard ratio of 6.42. An increase from 4 to 6 mg/dL yields a hazard ratio of 2.05, and an increase from 10 to 12 mg/dL yields a hazard ratio of 1.17. Among patients who were deeply jaundiced, survival was related to the absence of multiorgan failure and to higher platelet counts. In conclusion, the value of total serum bilirubin at a particular point in time after transplant carries more informative prognostic information than does the maximum or average value up to that point in time. The increase in mortality for a given increase in bilirubin value is larger when the starting value is lower.
MeSH term(s)	Adolescent ; Adult ; Aged ; Bilirubin/blood ; Child ; Child, Preschool ; Cohort Studies ; Female ; Hematopoietic Stem Cell Transplantation/mortality ; Humans ; Hyperbilirubinemia/physiopathology ; Infant ; Jaundice/blood ; Jaundice/complications ; Jaundice/mortality ; Male ; Middle Aged ; Multiple Organ Failure/etiology ; Myeloablative Agonists/therapeutic use ; Platelet Count ; Proportional Hazards Models ; Severity of Illness Index ; Time Factors ; Transplantation, Homologous
Chemical Substances	Myeloablative Agonists ; Bilirubin (RFM9X3LJ49)
Language	English
Publishing date	2005-02
Publishing country	United States
Document type	Journal Article ; Research Support, U.S. Gov't, P.H.S.
ZDB-ID	604603-4
ISSN	1527-3350 ; 0270-9139
ISSN (online)	1527-3350
ISSN	0270-9139
DOI	10.1002/hep.20529
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1660: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality.

McCune, Jeannine S / Batchelder, Ami / Deeg, H Joachim / Gooley, Ted / Cole, Scott / Phillips, Brian / Schoch, H Gary / McDonald, George B

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

2007 Volume 13, Issue 7, Page(s) 853–862

Abstract: The pharmacokinetics of cyclophosphamide (CY) and its metabolites hydroxycyclophosphamide and carboxyethylphosphoramide mustard were determined in 75 patients receiving targeted oral busulfan followed by i.v. CY ((T)BU/CY) and in 147 patients receiving i. ...

Abstract	The pharmacokinetics of cyclophosphamide (CY) and its metabolites hydroxycyclophosphamide and carboxyethylphosphoramide mustard were determined in 75 patients receiving targeted oral busulfan followed by i.v. CY ((T)BU/CY) and in 147 patients receiving i.v. CY followed by total body irradiation (CY/TBI) in preparation for hematopoietic cell transplantation (HCT). In the (T)BU/CY patients only, the association of the pharmacokinetic data with liver toxicity, relapse, and survival was evaluated. CY was infused at 60 mg/kg/day over 1 or 2 hours on 2 consecutive days; the majority of patients had BU levels targeted to a steady state plasma concentration (Css) of 800-900 ng/mL. Systemic exposure (i.e., area under the concentration-time curve [AUC]) of CY, hydroxycyclophosphamide, and carboxyethylphosphoramide mustard was measured. Liver toxicity was assessed as the development of hepatic sinusoidal obstruction syndrome (SOS). CY metabolism was highly variable and age dependent. (T)BU/CY-treated patients had lower AUC(CY) (P < .0001), higher AUC(HCY) (P < .0001), and higher AUC(CEPM) (P = .15) than CY/TBI-conditioned patients. Among patients receiving (T)BU/CY, 17 (23%) developed SOS, and there were no statistically significant associations between the AUC of CY or its metabolites and SOS, nonrelapse mortality, relapse, or survival (all P >.15). In conclusion, CY exhibits conditioning-regimen dependent pharmacokinetics and pharmacodynamics, suggesting that lowering CY doses is unlikely to improve outcomes to (T)BU/CY. Alternative strategies, such as administering i.v. busulfan or CY before BU, should be explored.
MeSH term(s)	Administration, Oral ; Adolescent ; Adult ; Aged ; Busulfan/administration & dosage ; Busulfan/adverse effects ; Busulfan/pharmacokinetics ; Chemical and Drug Induced Liver Injury ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/adverse effects ; Cyclophosphamide/pharmacokinetics ; Disease-Free Survival ; Female ; Hematologic Neoplasms/mortality ; Hematologic Neoplasms/therapy ; Hematopoietic Stem Cell Transplantation ; Humans ; Liver Diseases/mortality ; Male ; Middle Aged ; Survival Rate ; Syndrome ; Transplantation Conditioning ; Whole-Body Irradiation/adverse effects
Chemical Substances	Cyclophosphamide (8N3DW7272P) ; Busulfan (G1LN9045DK)
Language	English
Publishing date	2007-07
Publishing country	United States
Document type	Clinical Trial ; Journal Article ; Research Support, N.I.H., Extramural
ZDB-ID	1474865-4
ISSN	1083-8791
ISSN	1083-8791
DOI	10.1016/j.bbmt.2007.03.012
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5082: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 462: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Gastrointestinal graft-versus-host disease in recipients of autologous hematopoietic stem cells: incidence, risk factors, and outcome.

Holmberg, Leona / Kikuchi, Kaoru / Gooley, Ted A / Adams, Kristina M / Hockenbery, David M / Flowers, Mary E D / Schoch, H Gary / Bensinger, William / McDonald, George B

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

2006 Volume 12, Issue 2, Page(s) 226–234

Abstract: Graft-versus-host disease (GVHD) is seen in skin, intestinal mucosa, and liver after autologous stem cell transplantation. We reviewed 681 consecutive patients to estimate the probability of gastrointestinal (GI) GVHD, response to treatment, risk factors ...

Abstract	Graft-versus-host disease (GVHD) is seen in skin, intestinal mucosa, and liver after autologous stem cell transplantation. We reviewed 681 consecutive patients to estimate the probability of gastrointestinal (GI) GVHD, response to treatment, risk factors for development, and effect on survival. GI GVHD was defined by persistent symptoms, mucosal abnormalities at endoscopy, and histology showing apoptotic crypt cells with or without lymphoid infiltrates. The proportion of patients with GI GVHD was 90/681 (13%). Nausea and vomiting occurred in 90% and diarrhea in 40%. The mean time to developing symptoms was day +15, that to histologically proven diagnosis was day +42, and that to starting prednisone treatment was day +45 after stem cell infusion. Treatment with a short course of prednisone effected durable responses in 79% of patients, and an additional 18% responded to a second course of prednisone. A multivariable logistic regression model demonstrated that the combined factor of a diagnosis of breast cancer or hematologic malignancy and female sex was statistically significantly associated with the probability of GI GVHD (P = .003). Survival in patients with GI GVHD was not statistically different than that in those without GVHD. We conclude that women with breast cancer or hematologic malignancy are more likely to develop GI GVHD after autologous transplantation, and that treatment with prednisone was effective.
MeSH term(s)	Adult ; Anti-Inflammatory Agents/administration & dosage ; Female ; Gastrointestinal Diseases/drug therapy ; Gastrointestinal Diseases/mortality ; Graft vs Host Disease/drug therapy ; Graft vs Host Disease/mortality ; Hematopoietic Stem Cell Transplantation/methods ; Hematopoietic Stem Cell Transplantation/mortality ; Humans ; Incidence ; Male ; Middle Aged ; Neoplasms/mortality ; Neoplasms/therapy ; Prednisone/administration & dosage ; Pregnancy ; Pregnancy Complications, Neoplastic/mortality ; Pregnancy Complications, Neoplastic/therapy ; Retrospective Studies ; Risk Factors
Chemical Substances	Anti-Inflammatory Agents ; Prednisone (VB0R961HZT)
Language	English
Publishing date	2006-02
Publishing country	United States
Document type	Case Reports ; Journal Article ; Research Support, N.I.H., Extramural
ZDB-ID	1474865-4
ISSN	1083-8791
ISSN	1083-8791
DOI	10.1016/j.bbmt.2005.10.011
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5082: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 462: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients.

Hogan, William J / Maris, Michael / Storer, Barry / Sandmaier, Brenda M / Maloney, David G / Schoch, H Gary / Woolfrey, Ann E / Shulman, Howard M / Storb, Rainer / McDonald, George B

Blood

2003 Volume 103, Issue 1, Page(s) 78–84

Abstract: Liver injury is a frequent, serious complication of allogeneic hematopoietic cell transplantation (HCT) following myeloablative preparative regimens. We sought to determine the frequency and severity of hepatic injury after nonmyeloablative conditioning ... ...

Abstract	Liver injury is a frequent, serious complication of allogeneic hematopoietic cell transplantation (HCT) following myeloablative preparative regimens. We sought to determine the frequency and severity of hepatic injury after nonmyeloablative conditioning and its relationship to outcomes. One hundred ninety-three consecutive patients who received 2 Gy total body irradiation with or without fludarabine were evaluated for end points related to liver injury. Patients with diseases treatable by HCT who were ineligible for conventional myeloablative allogeneic HCT because of advanced age and/or comorbid conditions were included. Fifty-one patients (26%) developed hyperbilirubinemia of 68.4 microM (4 mg/dL) or greater, most commonly resulting from cholestasis due to graft-versus-host disease (GVHD) or sepsis. Pretransplantation factors associated with liver dysfunction were a diagnosis of aggressive malignancy (hazard ratio [HR] 1.9; P =.04) and the inclusion of fludarabine in the conditioning regimen (HR 1.8; P =.07). Overall survival at 1 year was superior for patients who had maximal serum bilirubin levels in the normal (78%) or minimally elevated (22.23-66.69 microM [1.3-3.9 mg/dL]) ranges (69%) compared with those in the 68.4 to 117.99 microM (4-6.9 mg/dL; 20%), 119.7 to 169.29 microM (7.0-9.9 mg/dL; 17%), and 171.0 microM (10 mg/dL; 19%) or greater groups. In summary, significant jaundice occurred in 26% of patients and was predominantly due to cholestasis resulting from GVHD and/or sepsis. Aggressive malignancies (mainly advanced disease) and later development of jaundice after transplantation predicted inferior survival.
MeSH term(s)	Adolescent ; Adult ; Aged ; Child ; Child, Preschool ; Female ; Hematopoietic Stem Cell Transplantation/adverse effects ; Hematopoietic Stem Cell Transplantation/mortality ; Humans ; Hyperbilirubinemia/etiology ; Infant ; Liver/injuries ; Liver/physiopathology ; Male ; Middle Aged ; Risk Factors ; Survival Rate ; Transplantation Conditioning/adverse effects ; Transplantation Conditioning/methods ; Transplantation Conditioning/mortality ; Transplantation, Homologous
Language	English
Publishing date	2003-09-11
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S. ; Research Support, U.S. Gov't, P.H.S.
ZDB-ID	80069-7
ISSN	1528-0020 ; 0006-4971
ISSN (online)	1528-0020
ISSN	0006-4971
DOI	10.1182/blood-2003-04-1311
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.140: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 364: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation.

McDonald, George B / Slattery, John T / Bouvier, Michelle E / Ren, Song / Batchelder, Ami L / Kalhorn, Thomas F / Schoch, H Gary / Anasetti, Claudio / Gooley, Ted

Blood

2002 Volume 101, Issue 5, Page(s) 2043–2048

Abstract: Liver toxicity caused by high-dose myeloablative therapy leads to significant morbidity after hematopoietic cell transplantation. We examined the hypothesis that liver toxicity after cyclophosphamide and total body irradiation is related to ... ...

Abstract	Liver toxicity caused by high-dose myeloablative therapy leads to significant morbidity after hematopoietic cell transplantation. We examined the hypothesis that liver toxicity after cyclophosphamide and total body irradiation is related to cyclophosphamide through its metabolism to toxins. Cyclophosphamide was infused at 60 mg/kg over 1 to 2 hours on each of 2 consecutive days, followed by total body irradiation. Plasma was analyzed for cyclophosphamide and its major metabolites. Liver toxicity was scored by the development of sinusoidal obstruction syndrome (veno-occlusive disease) and by total serum bilirubin levels. The hazards of liver toxicity, nonrelapse mortality, tumor relapse, and survival were calculated using regression analysis that included exposure to cyclophosphamide metabolites (as the area under the curve). Of 147 patients, 23 (16%) developed moderate or severe sinusoidal obstruction syndrome. The median peak serum bilirubin level through day 20 was 2.6 mg/dL (range, 0.5-41.1 mg/dL). Metabolism of cyclophosphamide was highly variable, particularly for the metabolite o-carboxyethyl-phosphoramide mustard, whose area under the curve varied 16-fold. Exposure to this metabolite was statistically significantly related to sinusoidal obstruction syndrome, bilirubin elevation, nonrelapse mortality, and survival, after adjusting for age and irradiation dose. Patients in the highest quartile of o-carboxyethyl-phosphoramide mustard exposure had a 5.9-fold higher risk for nonrelapse mortality than did patients in the lowest quartile. Engraftment and tumor relapse were not statistically significantly related to cyclophosphamide metabolite exposure. Increased exposure to toxic metabolites of cyclophosphamide leads to increased liver toxicity and nonrelapse mortality and lower overall survival after hematopoietic cell transplantation.
MeSH term(s)	Adolescent ; Adult ; Area Under Curve ; Biotransformation ; Chemical and Drug Induced Liver Injury/epidemiology ; Chemical and Drug Induced Liver Injury/etiology ; Child ; Child, Preschool ; Cyclophosphamide/adverse effects ; Cyclophosphamide/blood ; Cyclophosphamide/pharmacokinetics ; Female ; Hematologic Neoplasms/therapy ; Hepatic Veno-Occlusive Disease/chemically induced ; Hepatic Veno-Occlusive Disease/epidemiology ; Hepatocytes/metabolism ; Humans ; Hyperbilirubinemia/chemically induced ; Hyperbilirubinemia/epidemiology ; Leukocyte Count ; Male ; Middle Aged ; Neutrophils ; Peripheral Blood Stem Cell Transplantation/mortality ; Phosphoramide Mustards/adverse effects ; Phosphoramide Mustards/blood ; Platelet Count ; Prospective Studies ; Recurrence ; Survival Analysis ; Transplantation Conditioning/adverse effects ; Transplantation Conditioning/mortality ; Whole-Body Irradiation
Chemical Substances	Phosphoramide Mustards ; carboxyethylphosphoramide mustard ; Cyclophosphamide (8N3DW7272P)
Language	English
Publishing date	2002-10-24
Publishing country	United States
Document type	Journal Article ; Research Support, U.S. Gov't, P.H.S.
ZDB-ID	80069-7
ISSN	1528-0020 ; 0006-4971
ISSN (online)	1528-0020
ISSN	0006-4971
DOI	10.1182/blood-2002-06-1860
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.140: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 364: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito